

IRODALOM *

- 1 Alcock GS, Liley H.
Immunoglobulin infusion for isoimmune hemolytic jaundice in neonates.
Cochrane Database Syst Rev. 2002; (3): CD 00 33 13.
- 2 American Academy of Pediatrics.
Management of Hyperbilirubinemia in the Newborn Infant 35 or More Weeks of Gestation.
Pediatrics. 2004; 114: 297-316.
- 3 Anthony RM et al.
Intravenous immunoglobulin suppresses inflammation through a novel T_H2 pathway.
Nature. 2011; 475: 110-3.
- 3a Supplementary Information. – Annex to the previous item (3) –Full-Text (HTML)
Anthony RM et al.
Intravenous immunoglobulin suppresses inflammation through a novel T_H2 pathway.
Nature. 2011; 475: 110-3.
- 4 Anthony RM et al.
Novel roles for the IgG Fc glycan.
Ann NY Acad Sci. 2012; 1253: 170-80.
- 5 Boros P et al.
High Dose Intravenous Immunoglobulin Treatment: Mechanisms of Action.
Liver Transpl. 2005; 11(12): 1469-80.
- 6 Bhutani VK et al.
Management of jaundice and prevention of severe neonatal hyperbilirubinemia in infants
> or = 35 weeks gestation.
Neonatology. 2008; 94(1): 163-7.
- 7 De Boer IP et al.
Pediatric outcome of Rhesus hemolytic disease treated with or without intrauterine
transfusion.
Am J Obstet Gynecol. 2008; 198: 54.e1-4.
- 8 Durandy A et al.
Intravenous immunoglobulins – understanding properties and mechanisms.
Clin Exper Immunol. 2009; 158(Suppl 1): 2-13.
- 9 Elaffy MS et al.
Early intravenous immunoglobulin (two-dose regimen) in the management of severe
Rh hemolytic disease of newborn – a prospective randomized trial.
Eur J Pediatr. 2011; 170: 461-7.
- 10 Girish G et al.
Efficacy of two dose regimes of intravenous immunoglobulin in Rh hemolytic disease of
newborn– a randomized controlled trial.
Indian Pediatr. 2008; 45(8): 653-9.
- 11 Goddard EA.
Intravenous immunoglobulin.
Curr Allergy & Clin Immunol. 2008; 21(1): 26-31.

- 12 Gottstein R, Cooke RW.
Systematic review of intravenous immunoglobulin in haemolytic disease of the newborn.
Arch Dis Child Fetal Neonatal Ed. 2003; 88(1): F6-10.
- 13 Heyborne K.
Elevated Middle Cerebral Artery Peak Systolic Velocity in a nonanemic Fetus
With Alpha-Thalassemia Trait.
Obstet Gynecol Int. 2009; 2009. 819380.
- 14 Imbach P.
30 years of immunomodulation by intravenous immunoglobulin.
Immunotherapy. 2012; 4(7): 651-4.
- 15 Imbach P, Lazarus AH, Kükne T.
Intravenous immunoglobulins induce potentially synergistic immunomodulations
in autoimmune disorders.
Vox Sang. 2010; 98(3 Pt2): 385-94.
- 16 Kavanaugh A, Broide D.
Immunomodulators.
In: Middleton's Allergy: Principles and Practice, 7th ed. Mosby, Elsevier, Philadelphia,
2008, Chapter 94.
- 17 Kessary-Shohan H et al.
In vivo administration of intravenous immunoglobulin (IVIg) can lead to enhanced
erythrocyte sequestration.
J autoimmun. 1999; 13(1): 129-35.
- 18 Maddur MS et al.
Immunomodulation by intravenous Immunoglobulin: Role of Regulatory T Cells.
J Clin Immunol. 2010; 30(Suppl 1): 54-8.
- 19 Maheshwari A, Carlo WA.
97.2 Hemolytic Disease of the Newborn (Erythroblastosis Fetalis).
In: Nelson Textbook of Pediatrics, 19th ed. Saunders, Elsevier, Philadelphia. 2011,
Chapter 97: Blood Disorders
- 20 Mari G et al.
Diagnosis of fetal anemia with Doppler ultrasound in the pregnancy complicated
by maternal blood group immunization.
Ultrasound Obstet Gynecol. 1995; 5: 400-5.
- 21 Monpoux F et al.
[High-dose intravenous immunoglobulin therapy and neonatal jaundice due to
red blood cell alloimmunization].
[Article in French].
Arch Pediatr. 2009; 16(9): 1289-94.
- 22 Murray NA, Roberts IA.
Haemolytic disease of the newborn.
Arch Dis Child Fetal Neonatal Ed. 2007; 92(2): F83-8.
- 23 Nagy A, Lakatos L.
[Treatment of infants with severe haemolytic diseases without exchange transfusion].
[Article in Hungarian with English Abstract]
Gyermekgyógyászat. 2011; 62: 153-5.

- 24 Navarro M et al.
Necrotizing enterocolitis following the use of intravenous immunoglobulin for haemolytic disease of the newborn.
Acta Paediatr. 2009; 98(7): 1214-7.
- 25 Posencheg MA, Dennery PA.
Hemolytic Disease of the Fetus and Newborn,
In: Conn's Current Therapy, 1st ed. Saunders, Elsevier, Philadelphia, 2012,
Chapter 20: Children's Health.
- 26 Robinson P et al.
Evidence-based guidelines of the use of intravenous immune globulin for hematologic and neurologic conditions.
Transfus Med Rev. 2007; 21(2 Suppl 1): 53-8.
- 27 Ruma MS et al.
Combined plasmapheresis and intravenous immune globulin for the treatment of severe maternal red cell alloimmunization.
Am J Obstet Gynecol. 2007; 196; 138.e1-6
- 28 Sewell WA, Jolles S.
Immunomodulatory action of intravenous immunoglobulin.
Immunology. 2002; 107(4): 387-93.
- 29 Smits-Wintjens VE et al.
Intravenous immunoglobulin in neonates with rhesus hemolytic disease:
a randomized controlled trial.
Pediatrics. 2011; 127(4): 680-6
- 30 Szende K et al.
[Erythroblastosis fetalis – Only in the past?].
[Abstract in Hungarian]
(Oral presentation, Annual Meeting,
Hungarian Paediatric Association. Tapolca, 2012 Sept 6-8.)
Gyermekgyógyászat. 2012; 63: 242-3.
- 31 Tamada A et al.
Hemolytic anemia following high-dose intravenous immunoglobulin administration.
Acta Paediatr Jpn. 1995; 37(3): 391-3.
- 32 Yousuf R et al.
Hemolytic disease of the fetus and newborn caused by anti-D and anti-S alloantibodies:
a case report.
J Med Case Rep. 2012; 6(1): 71.

*** Megjegyzés** (az érdeklődő olvasók részére) :

- Az anyag túlnyomó része (kivéve: 1., 6., 10., 23., 30. és 31. sz. abstract-ot)
Full-Text-ben is megtalálható a továbbiakban..
- A tankönyv, kézikönyv (fejezet, – 16., 19. és 25. sz. –) a Klinika tagjai számára az
(egyébként is rendkívül célszerűen és eredményesen hasznosítható adatbázis !)
MDConsult-on, egyszerű regisztrációval elérhetően rendelkezésre áll.